c-Abl (ABL1) phosphorylates α-synuclein at Y39, promoting aggregation and neuronal toxicity. Nilotinib (FDA-approved for CML) inhibits c-Abl and promotes α-syn clearance via autophagy, representing a rapid translational candidate. However, the hypothesis faces significant challenges: (1) Y39 phosphorylation is less abundant than S129 in human synucleinopathies and its aggregation role is contested; (2) Nilotinib failed its primary endpoint in PD clinical trials (Ko et al. 2020) with no UPDRS improvement; (3) BBB penetration claims are disputed; (4) Nilotinib has multiple off-target effects (DDR1, DDR2) that may explain any apparent neuroprotection independent of c-Abl. The Mechanism Attribution Problem is severe—any observed benefit cannot be confidently assigned to c-Abl inhibition.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["ABL1/c-Abl Tyrosine Kinase Activation"]
B["Mitochondrial Dysfunction"]
C["Oxidative Stress"]
D["p53 Activation Pro-apoptotic Signaling"]
E["Synaptic Dysfunction"]
F["Neuronal Death"]
G["Dasatinib / Nilotinib Kinase Inhibition"]
A --> B
B --> C
C --> D
D --> F
A --> E
E --> F
G --> A
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for ABL1 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations1 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
4
MECH 4CLIN 4GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
c-Abl phosphorylates α-syn at Y39 promoting aggreg…
Nilotinib crosses BBB and reduces α-syn in preclinical models
c-Abl activity elevated in PD substantia nigra; PMID related
Nilotinib FDA-approved for CML—established safety and manufacturing
✗ Opposing Evidence
4
Ko et al. 2020 trial failed primary endpoint (UPDRS)—no clinical efficacy despite CSF α-syn reduction
Y39 phosphorylation is minor modification vs S129; role in aggregation contested
Nilotinib has multiple off-target kinases (DDR1, DDR2); benefit cannot be attributed to c-Abl
BBB penetration claims disputed—therapeutic concentrations in SN uncertain
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theoretical Analysis: C1q-Driven Synaptic Pruning in Alzheimer's Disease
Key Molecular Mechanisms
C1q initiates the classical complement cascade, binding directly to synapses in an activity-independent manner—distinct from developmental pruning, which selectively eliminates less-active terminals. This pathway operates through sequential molecular events:
C1q deposition: Upregulated by astrocytes and neurons in AD brain, binding exposed phosphatidylserine on stressed synapses (Hong et al. 2016, PMID 27339137)
C3 convertase formation: C1q triggers C4/C2 cleavage, genera
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The hypothesis presents an elegant mechanistic framework linking amyloid oligomers to complement-driven synaptic loss, with therapeutic translation via ANX005. While the molecular pathway is biologically plausible and supported by experimental data, the theoretical analysis contains significant weaknesses that warrant scrutiny.
1. Causal Direction Remains Unresolved
The hypothesis assumes C1q upregulation drives synaptic loss in AD. However, C1q has established roles in synaptic maintenance and pr
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Translation Assessment: C1q as a Therapeutic Target in AD
Druggability — Favorable but Complex
C1q is a well-characterized target with validated biology. ANX005 (Anixa Biosciences), a monoclonal antibody against C1q, represents the primary clinical asset. It completed a Phase 1 study (NCT04592302) in healthy volunteers establishing initial safety and pharmacokinetic profiles. The company subsequently explored ALS (NCT05037964), but AD-specific development remains early-stage. Preclinical data in mouse models demonstrated reduced synaptic loss and preserved cognition, with
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"hypothesis_title": "Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Decline in Alzheimer's Disease","synthesis_summary": "The C1q-mediated synaptic pruning hypothesis presents a mechanistically compelling framework linking amyloid oligomers to complement-driven synapse loss through microglial phagocytosis via C3-CR3 signaling. While the molecular pathway is biologically plausible and supported by strong preclinical data including Hong et al. 2016, significant concerns remain about causal direction and whether complement activation represents a primary driver or a secondary
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF ABL1 knockout or ABL1 Y245F kinase-dead knock-in neurons are challenged with preformed α-synuclein fibrils, THEN Y39-phosphorylated α-synuclein will be reduced by >70% and aggregate burden will decrease compared to wild-type neurons, confirming ABL1 drives Y39 phosphorylation independent of off-target effects.
pendingconf: 0.55
Expected outcome: Y39-pS129 double-positive inclusions will be reduced by >70% in ABL1-deficient neurons; autophagy flux markers (LC3-II/LC3-I ratio) will not differ from baseline, indicating the clearance effect is c-Abl-dependent.
Falsified by: If Y39 phosphorylation and aggregate burden do not differ between ABL1 knockout and wild-type neurons (difference <20%), Y39 phosphorylation is driven by kinases other than ABL1 and the hypothesis is falsified; alternatively, if aggregate reduction occurs via autophagy induction despite absent c-Abl, nilotinib's mechanism is autophagy-induction rather than c-Abl inhibition.
Method: Human iPSC-derived dopaminergic neurons from 3 PD patients and 3 age-matched controls; CRISPR/Cas9-mediated ABL1 knockout via exon 2 deletion; α-synuclein PFF seeding assay at DIV 21; sequential extraction (TBS-soluble, Triton-soluble, SDS-insoluble) with immunoblot for Y39 (Abcam ab168381) and total α-synuclein (Syn1 BD Biosciences); 21-day treatment duration.
IF patients with idiopathic PD receive 6 months of nilotinib (300mg daily, the dose used in the Ko et al. 2020 trial) plus standard dopaminergic therapy versus placebo plus standard therapy, THEN striatal dopamine turnover (measured by F-DOPA PET) will show no significant difference between groups, indicating nilotinib provides no disease-modifying effect beyond symptomatic treatment.
pendingconf: 0.35
Expected outcome: No significant difference in F-DOPA Ki values between nilotinib and placebo groups after 6 months; projected effect size <0.15 standardized units.
Falsified by: If nilotinib-treated patients show ≥15% improvement in F-DOPA Ki at 6 months compared to placebo (p<0.05), the hypothesis that nilotinib's neuroprotective effects are attributable to c-Abl inhibition (and not off-target mechanisms) would be supported; however, this would require mechanistic replication with selective ABL1 inhibitors.
Method: Re-analysis of Ko et al. 2020 (NCT02954978) F-DOPA PET data, stratified by nilotinib pharmacokinetic exposure (plasma levels) and DDR1/DDR2 genotyping to test whether higher c-Abl target engagement (rather than total drug exposure) predicts outcomes.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
ABL1 — Search for structure
Click to search RCSB PDB